Comparison of two probiotics in follow-on formula: Bifidobacterium animalis subsp. lactis HN019 reduced upper respiratory tract infections in Chinese infants
In: Beneficial MicrobesSearch for other papers by J. Dekker in
Current site
Google Scholar
Search for other papers by M. Quilter in
Current site
Google Scholar
Search for other papers by H. Qian in
Current site
Google Scholar
A randomised, double-blind, placebo-controlled trial was performed to investigate the health benefits of probiotic bacteria in infants when delivered in a follow-on infant formula. The study was conducted in Fuyang (Anhui Province, China) during winter and enrolled 192 healthy infants aged six to 12 months. Infants received one of three follow-on formulae daily for 12 weeks: supplemented with 106 cfu/g Bifidobacterium animalis subsp. lactis HN019 (n=64); 106 cfu/g Lacticaseibacillus rhamnosus HN001 (n=64); or without added probiotics (n=64). The primary endpoint was physician-confirmed bacterial or viral infections during the treatment period. Secondary endpoints included parentally reported (confirmed and unconfirmed) infections; antiviral or antibiotic treatments, and hospitalisation; stool frequency and consistency; infant growth; infant temperament; and adverse events. There were 8 cases of confirmed infection, all upper respiratory tract infections (URTIs). Confirmed URTIs were observed in 9.4% of the control group, compared to 3.1% in the HN001 group (P=0.273), and 0.0% in the HN019 group (P=0.028). A similar trend was observed for parentally reported URTIs, with 25.0% in the control group, compared with 14.1% in the HN001 group (P=0.119) and 9.4% in the HN019 group (P=0.019). No infants in the HN019 group were prescribed antibiotics or antivirals, compared with 3 (4.7%) in the HN001 group and 7 (10.9%) in the control group. No infants required hospitalisation. The probiotic-containing formulae were well-tolerated: there were no cases of diarrhoea or differences in stool frequency or characteristics, no differences in infant growth or temperament, and no treatment-related adverse events. This study directly compared the benefits of two different probiotics when added to follow-on infant formula at 106 cfu/g and consumed over a 12-week period. While HN001 showed trends toward reduced infections, HN019 showed better performance in terms of significantly reduced incidence of both physician-confirmed and parentally reported URTIs, and antibiotic/antiviral use compared to a control in Chinese infants.
The trial is registered at ClinicalTrials.gov (NCT01724203).
-
Agustina, R., Kok, F.J., van de Rest, O., Fahmida, U., Firmansyah, A., Lukito, W., Feskens, E.J., van den Heuvel, E.G. Albers, R. and Bovee-Oudenhoven, I.M., 2012. Randomized trial of probiotics and calcium on diarrhea and respiratory tract infections in Indonesian children. Pediatrics 129: e1155-1164.
'Randomized trial of probiotics and calcium on diarrhea and respiratory tract infections in Indonesian children ' () 129 Pediatrics : e1155 -1164.
-
Anonymous, 2015. Translated Chinese GB Standards: Appendix 3 Regulation and National Standards – Dairy. Available at: https://www.mpi.govt.nz/dmsdocument/14380.
-
Bates, J.E., Freeland, C.A. and Lounsbury, M.L., 1979. Measurement of infant difficultness. Child Development 50: 794-803.
'Measurement of infant difficultness ' () 50 Child Development : 794 -803.
-
Bernini, L.J., Simao, A.N., Alfieri, D.F., Lozovoy, M.A., Mari, N.L., de Souza, C.H., Dichi, I. and Costa, G.N., 2016. Beneficial effects of Bifidobacterium lactis on lipid profile and cytokines in patients with metabolic syndrome: A randomized trial. Effects of probiotics on metabolic syndrome. Nutrition 32: 716-719.
'Beneficial effects of Bifidobacterium lactis on lipid profile and cytokines in patients with metabolic syndrome: A randomized trial ' () 32 Nutrition : 716 -719.
-
Biasucci, G., Rubini, M., Riboni, S., Morelli, L., Bessi, E. and Retetangos, C., 2010. Mode of delivery affects the bacterial community in the newborn gut. Early Human Development 86 Suppl 1: 13-15.
'Mode of delivery affects the bacterial community in the newborn gut ' () 86 Early Human Development : 13 -15.
-
Braegger, C., Chmielewska, A., Decsi, T., Kolacek, S., Mihatsch, W., Moreno, L., Piescik, M., Puntis, J., Shamir, R., Szajewska, H., Turck, D. and van Goudoever, J., 2011. Supplementation of infant formula with probiotics and/or prebiotics: a systematic review and comment by the ESPGHAN committee on nutrition. Journal of Pediatric Gastroenterology and Nutrition 52: 238-250.
'Supplementation of infant formula with probiotics and/or prebiotics: a systematic review and comment by the ESPGHAN committee on nutrition ' () 52 Journal of Pediatric Gastroenterology and Nutrition : 238 -250.
-
Dekker, J.W., Wickens, K., Black, P.N., Stanley, T.V., Mitchell, E.A., Fitzharris, P., Tannock, G.W., Purdie, G. and Crane, J., 2009. Safety aspects of probiotic bacterial strains Lactobacillus rhamnosus HN001 and Bifidobacterium animalis subsp. lactis HN019 in human infants aged 0-2 years. International Dairy Journal 19: 149-154.
'Safety aspects of probiotic bacterial strains Lactobacillus rhamnosus HN001 and Bifidobacterium animalis subsp. lactis HN019 in human infants aged 0-2 years ' () 19 International Dairy Journal : 149 -154.
-
Dominguez-Bello, M.G., Costello, E.K., Contreras, M., Magris, M., Hidalgo, G., Fierer, N. and Knight, R., 2010. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proceedings of the National Academy of Sciences of the United States of America 107: 11971-11975.
'Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns ' () 107 Proceedings of the National Academy of Sciences of the United States of America : 11971 -11975.
-
Fernandez, L., Langa, S., Martin, V., Maldonado, A., Jimenez, E., Martin, R. and Rodriguez, J.M., 2013. The human milk microbiota: origin and potential roles in health and disease. Pharmacological Research 69: 1-10.
'The human milk microbiota: origin and potential roles in health and disease ' () 69 Pharmacological Research : 1 -10.
-
Food and Agriculture Organization of the United Nations/World Health Organization (FAO/WHO), 2002. Guidelines for the evaluation of probiotics in food. Report of a Joint FAO/WHO Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food. Available at: https://www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf.
-
Gill, H.S., Rutherfurd, K.J. and Cross, M.L., 2001a. Dietary probiotic supplementation enhances natural killer cell activity in the elderly: an investigation of age-related immunological changes. Journal of Clinical Immunology 21: 264-271.
'Dietary probiotic supplementation enhances natural killer cell activity in the elderly: an investigation of age-related immunological changes ' () 21 Journal of Clinical Immunology : 264 -271.
-
Gill, H.S., Shu, Q., Lin, H., Rutherfurd, K.J. and Cross, M.L., 2001b. Protection against translocating Salmonella typhimurium infection in mice by feeding the immuno-enhancing probiotic Lactobacillus rhamnosus strain HN001. Medical Microbiology and Immunology 190: 97-104.
'Protection against translocating Salmonella typhimurium infection in mice by feeding the immuno-enhancing probiotic Lactobacillus rhamnosus strain HN001 ' () 190 Medical Microbiology and Immunology : 97 -104.
-
Gopal, P.K., Prasad, J. and Gill, H.S., 2003. Effects of the consumption of Bifidobacterium lactis HN019 (DR10TM) and galactooligosaccharides on the microflora of the gastrointestinal tract in human subjects. Nutrition Research 23: 1313-1328.
'Effects of the consumption of Bifidobacterium lactis HN019 (DR10TM) and galactooligosaccharides on the microflora of the gastrointestinal tract in human subjects ' () 23 Nutrition Research : 1313 -1328.
-
Guarino, A., Ashkenazi, S., Gendrel, D., Lo Vecchio, A., Shamir, R. and Szajewska, H., 2014. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014. Journal of Pediatric Gastroenterology and Nutrition 59: 132-152.
'European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014 ' () 59 Journal of Pediatric Gastroenterology and Nutrition : 132 -152.
-
Guarino, A., Canani, R.B., Spagnuolo, M.I., Albano, F. and Di Benedetto, L., 1997. Oral bacterial therapy reduces the duration of symptoms and of viral excretion in children with mild diarrhea. Journal of Pediatric Gastroenterology and Nutrition 25: 516-519.
'Oral bacterial therapy reduces the duration of symptoms and of viral excretion in children with mild diarrhea ' () 25 : 516 -519.
-
Gutierrez-Castrellon, P., Lopez-Velazquez, G., Diaz-Garcia, L., Jimenez-Gutierrez, C., Mancilla-Ramirez, J., Estevez-Jimenez, J. and Parra, M., 2014. Diarrhea in preschool children and Lactobacillus reuteri: a randomized controlled trial. Pediatrics 133: e904-909.
'Diarrhea in preschool children and Lactobacillus reuteri: a randomized controlled trial ' () 133 Pediatrics : e904 -909.
-
Hao, Q., Dong, B.R. and Wu, T., 2015. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database of Systematic Reviews: Cd006895.
'Probiotics for preventing acute upper respiratory tract infections ' () Cochrane Database of Systematic : Cd006895.
-
Hay, A.D., Heron, J. and Ness, A., 2005. The prevalence of symptoms and consultations in pre-school children in the Avon Longitudinal Study of Parents and Children (ALSPAC): a prospective cohort study. Family Practice 22: 367-374.
'The prevalence of symptoms and consultations in pre-school children in the Avon Longitudinal Study of Parents and Children (ALSPAC): a prospective cohort study ' () 22 Family Practice : 367 -374.
-
He, Q., Wang, M., Xu, J., Zhang, C., Wang, H., Zhu, W. and Fu, C., 2013. Rotavirus vaccination coverage among children aged 2-59 months: a report from Guangzhou, China. PLoS ONE 8: e68169.
'Rotavirus vaccination coverage among children aged 2-59 months: a report from Guangzhou, China ' () 8 PLoS ONE : e68169.
-
Hemalatha, R., Ouwehand, A.C., Forssten, S.D., Babu Geddan, J.J., Mamidi, R.S., Bhaskar, V. and Radhakrishna, K.V., 2014. A community-based randomized double blind controlled trial of Lactobacillus paracasei and Bifidobacterium lactis on reducing risk for diarrhea and fever in preschool children in an urban slum in India. European Journal of Nutrition & Food Safety 4: 325-341.
'A community-based randomized double blind controlled trial of Lactobacillus paracasei and Bifidobacterium lactis on reducing risk for diarrhea and fever in preschool children in an urban slum in India ' () 4 European Journal of Nutrition & Food Safety : 325 -341.
-
Kang, E.J., Kim, S.Y., Hwang, I.H. and Ji, Y.J., 2013. The effect of probiotics on prevention of common cold: a meta-analysis of randomized controlled trial studies. Korean Journal of Family Medicine 34: 2-10.
'The effect of probiotics on prevention of common cold: a meta-analysis of randomized controlled trial studies ' () 34 Korean Journal of Family Medicine : 2 -10.
-
King, S., Glanville, J., Sanders, M.E., Fitzgerald, A. and Varley, D., 2014. Effectiveness of probiotics on the duration of illness in healthy children and adults who develop common acute respiratory infectious conditions: a systematic review and meta-analysis. British Journal of Nutrition 112: 41-54.
'Effectiveness of probiotics on the duration of illness in healthy children and adults who develop common acute respiratory infectious conditions: a systematic review and meta-analysis ' () 112 British Journal of Nutrition : 41 -54.
-
Kuang, YS., Li, SH., Guo, Y., Lu, JH., He, JR., Luo, BJ., Jiang, FJ., Shen, H., Papasian CJ., Pang, H., Zia, HM., Deng, HW., Qiu, X., 2016. Composition of gut microbiota in infants in China and global comparison. Scientific Reports 6: 36666.
'Composition of gut microbiota in infants in China and global comparison ' () 6 Scientific Reports : 36666.
-
Lewis, S.J. and Heaton, K.W., 1997. Stool form scale as a useful guide to intestinal transit time. Scandinavian Journal of Gastroenterology 32: 920-924.
'Stool form scale as a useful guide to intestinal transit time ' () 32 Scandinavian Journal of Gastroenterology : 920 -924.
-
Liu, L., Johnson, H.L., Cousens, S., Perin, J., Scott, S., Lawn, J.E., Rudan, I., Campbell, H., Cibulskis, R., Li, M., Mathers, C. and Black, R.E., 2012. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 379: 2151-2161.
'Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000 ' () 379 Lancet : 2151 -2161.
-
Liu, S., Hu, P., Du, X., Zhou, T. and Pei, X., 2013. Lactobacillus rhamnosus GG supplementation for preventing respiratory infections in children: a meta-analysis of randomized, placebocontrolled trials. Indian Pediatrics 50: 377-381.
'Lactobacillus rhamnosus GG supplementation for preventing respiratory infections in children: a meta-analysis of randomized, placebocontrolled trials ' () 50 Indian Pediatrics : 377 -381.
-
Miller, L.E., Lehtoranta, L. and Lehtinen, M.J., 2017. The Effect of Bifidobacterium animalis ssp. lactis HN019 on cellular immune function in healthy elderly subjects: systematic review and metaanalysis. Nutrients 9.
'The Effect of Bifidobacterium animalis ssp. lactis HN019 on cellular immune function in healthy elderly subjects: systematic review and metaanalysis ' () Nutrients : 9.
-
Moher, D., Hopewell, S., Schulz, K.F., Montori, V., Gotzsche, P.C., Devereaux, P.J., Elbourne, D., Egger, M. and Altman, D.G., 2010. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Journal of Clinical Epidemiology 63: e1-37.
'CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials ' () 63 Journal of Clinical Epidemiology : e1 -37.
-
Murphy, R., Morgan, X.C., Wang, X.Y., Wickens, K., Purdie, G., Fitzharris, P., Otal, A., Lawley, B., Stanley, T., Barthow, C., Crane, J., Mitchell, E.A. and Tannock, G.W., 2019. Eczema-protective probiotic alters infant gut microbiome functional capacity but not composition: sub-sample analysis from a RCT. Beneficial Microbes 10: 5-17.
'Eczema-protective probiotic alters infant gut microbiome functional capacity but not composition: sub-sample analysis from a RCT ' () 10 Beneficial Microbes : 5 -17.
-
Ozen, M., Kocabas Sandal, G. and Dinleyici, E.C., 2015. Probiotics for the prevention of pediatric upper respiratory tract infections: a systematic review. Expert Opinion on Biological Therapy 15: 9-20.
'Probiotics for the prevention of pediatric upper respiratory tract infections: a systematic review ' () 15 Expert Opinion on Biological Therapy : 9 -20.
-
Saeterdal, I., Underland, V. and Nilsen, E.S., 2012. The effect of probiotics for preventing acute upper respiratory tract infections. Global Advances in Health and Medicine 1: 124-125.
'The effect of probiotics for preventing acute upper respiratory tract infections ' () 1 Global Advances in Health and Medicine : 124 -125.
-
Sazawal, S., Dhingra, U., Hiremath, G., Sarkar, A., Dhingra, P., Dutta, A., Menon, V.P. and Black, R.E., 2010a. Effects of Bifidobacterium lactis HN019 and prebiotic oligosaccharide added to milk on iron status, anemia, and growth among children 1 to 4 years old. Journal of Pediatric Gastroenterology and Nutrition 51: 341-346.
'Effects of Bifidobacterium lactis HN019 and prebiotic oligosaccharide added to milk on iron status, anemia, and growth among children 1 to 4 years old ' () 51 Journal of Pediatric Gastroenterology and Nutrition : 341 -346.
-
Sazawal, S., Dhingra, U., Hiremath, G., Sarkar, A., Dhingra, P., Dutta, A., Verma, P., Menon, V.P. and Black, R.E., 2010b. Prebiotic and probiotic fortified milk in prevention of morbidities among children: community-based, randomized, double-blind, controlled trial. PLoS ONE 5: e12164.
'Prebiotic and probiotic fortified milk in prevention of morbidities among children: community-based, randomized, double-blind, controlled trial ' () 5 PLoS ONE : e12164.
-
Sheih, Y.H., Chiang, B.L., Wang, L.H., Liao, C.K. and Gill, H.S., 2001. Systemic immunity-enhancing effects in healthy subjects following dietary consumption of the lactic acid bacterium Lactobacillus rhamnosus HN001. Journal of the American College of Nutrition 20: 149-156.
'Systemic immunity-enhancing effects in healthy subjects following dietary consumption of the lactic acid bacterium Lactobacillus rhamnosus HN001 ' () 20 Journal of the American College of Nutrition : 149 -156.
-
Shu, Q. and Gill, H.S., 2001. A dietary probiotic (Bifidobacterium lactis HN019) reduces the severity of Escherichia coli O157:H7 infection in mice. Medical Microbiology and Immunology 189: 147-152.
'A dietary probiotic (Bifidobacterium lactis HN019) reduces the severity of Escherichia coli O157:H7 infection in mice ' () 189 Medical Microbiology and Immunology : 147 -152.
-
Shu, Q. and Gill, H.S., 2002. Immune protection mediated by the probiotic Lactobacillus rhamnosus HN001 (DR20) against Escherichia coli O157:H7 infection in mice. FEMS Immunology and Medical Microbiology 34: 59-64.
'Immune protection mediated by the probiotic Lactobacillus rhamnosus HN001 (DR20) against Escherichia coli O157:H7 infection in mice ' () 34 FEMS Immunology and Medical Microbiology : 59 -64.
-
Shu, Q., Lin, H., Rutherfurd, K.J., Fenwick, S.G., Prasad, J., Gopal, P.K. and Gill, H.S., 2000. Dietary Bifidobacterium lactis (HN019) enhances resistance to oral Salmonella typhimurium infection in mice. Microbiology and Immunology 44: 213-222.
'Dietary Bifidobacterium lactis (HN019) enhances resistance to oral Salmonella typhimurium infection in mice ' () 44 Microbiology and Immunology : 213 -222.
-
Skorka, A., Piescik-Lech, M., Kolodziej, M. and Szajewska, H., 2017. To add or not to add probiotics to infant formulae? An updated systematic review. Beneficial Microbes 8: 717-725.
'To add or not to add probiotics to infant formulae? An updated systematic review ' () 8 Beneficial Microbes : 717 -725.
-
Slykerman, R.F., Hood, F., Wickens, K., Thompson, J.M.D., Barthow, C., Murphy, R., Kang, J., Rowden, J., Stone, P., Crane, J., Stanley, T., Abels, P., Purdie, G., Maude, R., Mitchell, E.A. and the Probiotic in Pregnancy Study Group, 2017. Effect of LACTOBACILLUS RHAMNOSUS HN001 in pregnancy on postpartum symptoms of depression and anxiety: a randomised double-blind placebocontrolled trial. EBioMedicine 24: 159-165.
'Effect of LACTOBACILLUS RHAMNOSUS HN001 in pregnancy on postpartum symptoms of depression and anxiety: a randomised double-blind placebocontrolled trial ' () 24 EBioMedicine : 159 -165.
-
Szajewska, H., Guarino, A., Hojsak, I., Indrio, F., Kolacek, S., Shamir, R., Vandenplas, Y. and Weizman, Z., 2014. Use of probiotics for management of acute gastroenteritis: a position paper by the ESPGHAN Working Group for Probiotics and Prebiotics. Journal of Pediatric Gastroenterology and Nutrition 58: 531-539.
'Use of probiotics for management of acute gastroenteritis: a position paper by the ESPGHAN Working Group for Probiotics and Prebiotics ' () 58 Journal of Pediatric Gastroenterology and Nutrition : 531 -539.
-
Vouloumanou, E.K., Makris, G.C., Karageorgopoulos, D.E. and Falagas, M.E., 2009. Probiotics for the prevention of respiratory tract infections: a systematic review. International Journal of Antimicrobial Agents 34: 197.e191-110.
'Probiotics for the prevention of respiratory tract infections: a systematic review ' () 34 International Journal of Antimicrobial Agents : 197.e191 -110.
-
Waller, P.A., Gopal, P.K., Leyer, G.J., Ouwehand, A.C., Reifer, C., Stewart, M.E. and Miller, L.E., 2011. Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults. Scandinavian Journal of Gastroenterology 46: 1057-1064.
'Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults ' () 46 Scandinavian Journal of Gastroenterology : 1057 -1064.
-
Weizman, Z., Asli, G. and Alsheikh, A., 2005. Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. Pediatrics 115: 5-9.
'Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents ' () 115 Pediatrics : 5 -9.
-
Wickens, K., Black, P., Stanley, T.V., Mitchell, E., Barthow, C., Fitzharris, P., Purdie, G. and Crane, J., 2012. A protective effect of Lactobacillus rhamnosus HN001 against eczema in the first 2 years of life persists to age 4 years. Clinical and Experimental Allergy 42: 1071-1079.
'A protective effect of Lactobacillus rhamnosus HN001 against eczema in the first 2 years of life persists to age 4 years ' () 42 Clinical and Experimental Allergy : 1071 -1079.
-
Wickens, K., Black, P.N., Stanley, T.V., Mitchell, E., Fitzharris, P., Tannock, G.W., Purdie, G. and Crane, J., 2008. A differential effect of 2 probiotics in the prevention of eczema and atopy: a doubleblind, randomized, placebo-controlled trial. Journal of Allergy and Clinical Immunology 122: 788-794.
'A differential effect of 2 probiotics in the prevention of eczema and atopy: a doubleblind, randomized, placebo-controlled trial ' () 122 Journal of Allergy and Clinical Immunology : 788 -794.
-
Wickens, K., Stanley, T.V., Mitchell, E.A., Barthow, C., Fitzharris, P., Purdie, G., Siebers, R., Black, P.N. and Crane, J., 2013. Early supplementation with Lactobacillus rhamnosus HN001 reduces eczema prevalence to 6 years: does it also reduce atopic sensitization? Clinical & Experimental Allergy 43: 1048-1057.
'Early supplementation with Lactobacillus rhamnosus HN001 reduces eczema prevalence to 6 years: does it also reduce atopic sensitization? ' () 43 Clinical & Experimental Allergy : 1048 -1057.
-
Wickens, K.L., Barthow, C.A., Murphy, R., Abels, P.R., Maude, R.M., Stone, P.R., Mitchell, E.A., Stanley, T.V., Purdie, G.L., Kang, J.M., Hood, F.E., Rowden, J.L., Barnes, P.K., Fitzharris, P.F. and Crane, J., 2017. Early pregnancy probiotic supplementation with Lactobacillus rhamnosus HN001 may reduce the prevalence of gestational diabetes mellitus: a randomised controlled trial. British Journal of Nutrition 117: 804-813.
'Early pregnancy probiotic supplementation with Lactobacillus rhamnosus HN001 may reduce the prevalence of gestational diabetes mellitus: a randomised controlled trial ' () 117 British Journal of Nutrition : 804 -813.
-
World Health Organization (WHO), 2013. Review of the 2012-2013 winter influenza season, northern hemisphere. Available at https://www.who.int/publications/i/item/who-wer-8822-225-232.
-
Zhou, J.S. and Gill, H.S., 2005. Immunostimulatory probiotic Lactobacillus rhamnosus HN001 and Bifidobacterium lactis HN019 do not induce pathological inflammation in mouse model of experimental autoimmune thyroiditis. International Journal of Food Microbiology 103: 97-104.
'Immunostimulatory probiotic Lactobacillus rhamnosus HN001 and Bifidobacterium lactis HN019 do not induce pathological inflammation in mouse model of experimental autoimmune thyroiditis ' () 103 International Journal of Food Microbiology : 97 -104.
-
Zhou, J.S., Gopal, P.K. and Gill, H.S., 2001. Potential probiotic lactic acid bacteria Lactobacillus rhamnosus (HN001), Lactobacillus acidophilus (HN017) and Bifidobacterium lactis (HN019) do not degrade gastric mucin in vitro. International Journal of Food Microbiology 63: 81-90.
'Potential probiotic lactic acid bacteria Lactobacillus rhamnosus (HN001), Lactobacillus acidophilus (HN017) and Bifidobacterium lactis (HN019) do not degrade gastric mucin in vitro ' () 63 International Journal of Food Microbiology : 81 -90.
-
Zhou, J.S., Pillidge, C.J., Gopal, P.K. and Gill, H.S., 2005a. Antibiotic susceptibility profiles of new probiotic Lactobacillus and Bifidobacterium strains. International Journal of Food Microbiology 98: 211-217.
'Antibiotic susceptibility profiles of new probiotic Lactobacillus and Bifidobacterium strains ' () 98 International Journal of Food Microbiology : 211 -217.
-
Zhou, J.S., Rutherfurd, K.J. and Gill, H.S., 2005b. Inability of probiotic bacterial strains Lactobacillus rhamnosus HN001 and Bifidobacterium lactis HN019 to induce human platelet aggregation in vitro. Journal of Food Protection 68: 2459-2464.
'Inability of probiotic bacterial strains Lactobacillus rhamnosus HN001 and Bifidobacterium lactis HN019 to induce human platelet aggregation in vitro ' () 68 Journal of Food Protection : 2459 -2464.
-
Zhou, J.S., Shu, Q., Rutherfurd, K.J., Prasad, J., Birtles, M.J., Gopal, P.K. and Gill, H.S., 2000a. Safety assessment of potential probiotic lactic acid bacterial strains Lactobacillus rhamnosus HN001, Lb. acidophilus HN017, and Bifidobacterium lactis HN019 in BALB/c mice. International Journal of Food Microbiology 56: 87-96.
'Safety assessment of potential probiotic lactic acid bacterial strains Lactobacillus rhamnosus HN001, Lb. acidophilus HN017, and Bifidobacterium lactis HN019 in BALB/c mice ' () 56 International Journal of Food Microbiology : 87 -96.
-
Zhou, J.S., Shu, Q., Rutherfurd, K.J., Prasad, J., Gopal, P.K. and Gill, H.S., 2000b. Acute oral toxicity and bacterial translocation studies on potentially probiotic strains of lactic acid bacteria. Food and Chemical Toxicology 38: 153-161.
'Acute oral toxicity and bacterial translocation studies on potentially probiotic strains of lactic acid bacteria ' () 38 Food and Chemical Toxicology : 153 -161.
-
Zhou, L., Su, Q., Xu, Z., Feng, A., Jin, H., Wang, S. and Feng, Z., 2013. Seasonal influenza vaccination coverage rate of target groups in selected cities and provinces in China by season (2009/10 to 2011/12). PLoS ONE 8: e73724.
'Seasonal influenza vaccination coverage rate of target groups in selected cities and provinces in China by season (2009/10 to 2011/12) ' () 8 PLoS ONE : e73724.
-
Zong, X.N. and Li, H., 2013. Construction of a new growth references for China based on urban Chinese children: comparison with the WHO growth standards. PLoS ONE 8: e59569.
'Construction of a new growth references for China based on urban Chinese children: comparison with the WHO growth standards ' () 8 PLoS ONE : e59569.
Comparison of two probiotics in follow-on formula: Bifidobacterium animalis subsp. lactis HN019 reduced upper respiratory tract infections in Chinese infants
In: Beneficial MicrobesSearch for other papers by J. Dekker in
Current site
Google Scholar
PubMed
Search for other papers by M. Quilter in
Current site
Google Scholar
PubMed
Search for other papers by H. Qian in
Current site
Google Scholar
PubMed
A randomised, double-blind, placebo-controlled trial was performed to investigate the health benefits of probiotic bacteria in infants when delivered in a follow-on infant formula. The study was conducted in Fuyang (Anhui Province, China) during winter and enrolled 192 healthy infants aged six to 12 months. Infants received one of three follow-on formulae daily for 12 weeks: supplemented with 106 cfu/g Bifidobacterium animalis subsp. lactis HN019 (n=64); 106 cfu/g Lacticaseibacillus rhamnosus HN001 (n=64); or without added probiotics (n=64). The primary endpoint was physician-confirmed bacterial or viral infections during the treatment period. Secondary endpoints included parentally reported (confirmed and unconfirmed) infections; antiviral or antibiotic treatments, and hospitalisation; stool frequency and consistency; infant growth; infant temperament; and adverse events. There were 8 cases of confirmed infection, all upper respiratory tract infections (URTIs). Confirmed URTIs were observed in 9.4% of the control group, compared to 3.1% in the HN001 group (P=0.273), and 0.0% in the HN019 group (P=0.028). A similar trend was observed for parentally reported URTIs, with 25.0% in the control group, compared with 14.1% in the HN001 group (P=0.119) and 9.4% in the HN019 group (P=0.019). No infants in the HN019 group were prescribed antibiotics or antivirals, compared with 3 (4.7%) in the HN001 group and 7 (10.9%) in the control group. No infants required hospitalisation. The probiotic-containing formulae were well-tolerated: there were no cases of diarrhoea or differences in stool frequency or characteristics, no differences in infant growth or temperament, and no treatment-related adverse events. This study directly compared the benefits of two different probiotics when added to follow-on infant formula at 106 cfu/g and consumed over a 12-week period. While HN001 showed trends toward reduced infections, HN019 showed better performance in terms of significantly reduced incidence of both physician-confirmed and parentally reported URTIs, and antibiotic/antiviral use compared to a control in Chinese infants.
The trial is registered at ClinicalTrials.gov (NCT01724203).